Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Therapeutic inhibition of Epstein-Barr virus-associated tumor cell growth by dominant-negative EBNA1].

Uirusu - 1 Dec 2005

Imai Shosuke, Kuroda Masayuki, Yamashita Ryusuke, Ishiura Yoshihito

Abstract excerpt

Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1), a latent viral protein consistently expressed in infected proliferating cells, is essentially required in trans to maintain EBV episomes in cells. Thus EBNA1 will be an appropriate target for specific molecular therapy against EBV-associated cancers. We constructed a mutant (mt) EBNA1 lacking the N-terminal-half, relative to wild-type (wt) EBNA1, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Burkitt Lymphoma
Share to Cell Proliferation
Share to Epstein-Barr Virus Nuclear Antigens

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Therapy

Share to Herpesvirus 4, Human

Share to Plasmids

Share to Protein Structure, Tertiary

Share to Tumor Cells, Cultured

Source

Identifiers

PMID: 16557009
DOI: 10.2222/jsv.55.239

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Therapeutic inhibition of Epstein-Barr virus-associated tumor cell growth by dominant-negative EBNA1].PMID 16557009Read ↗

Eradication of Epstein-Barr virus episome and associated inhibition of infected tumor cell growth by adenovirus vector-mediated transduction of dominant-negative EBNA1.Semantic proximity Read ↗

Virally targeted therapies for EBV-associated malignancies.Semantic proximity Read ↗

The Epstein-Barr Virus EBNA1 ProteinSemantic proximity Read ↗

The EBV nuclear antigen 1 (EBNA1) enhances B cell immortalization several thousandfoldSemantic proximity Read ↗

Epstein–Barr virus‐encoded EBNA1 and ZEBRA : targets for therapeutic strategies against EBV ‐carrying cancersSemantic proximity Read ↗

Impact of EBV Essential Nuclear Protein EBNA-3C on B-Cell Proliferation and ApoptosisSemantic proximity Read ↗

Targeting EBV Episome for Anti-Cancer Therapy: Emerging Strategies and ChallengesSemantic proximity Read ↗

Dominant‐negative derivative of EBNA1 represses EBNA1‐mediated transforming gene expression during the acute phase of Epstein–Barr virus infection independent of rapid loss of viral genomeSemantic proximity Read ↗

Epstein–Barr virus: Induction and control of cell transformationSemantic proximity Read ↗

Dissecting Epstein–Barr Virus Dependence Across Diverse Infected Cell ModelsSemantic proximity Read ↗

A study of the Epstein Barr virus nuclear antigens EBNA3A and EBNA3C in vitro and in vivoSemantic proximity Read ↗

Epstein-Barr virus provides a survival factor to Burkitt's lymphomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.